Bain Capital Life Sciences Investors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,693,380
| Closed | -$1.44M | – | 26 |
|
|
2024
Q4 | $1.44M | Hold |
2,693,380
| – | – | 0.17% | 23 |
|
|
2024
Q3 | $4.74M | Buy |
2,693,380
+425,700
| +19% | +$594K | 0.49% | 21 |
|
|
2024
Q2 | $2.65M | Buy |
2,267,680
+874,300
| +63% | +$2.19M | 0.29% | 22 |
|
|
2024
Q1 | $12.6M | Sell |
1,393,380
-37,678
| -3% | -$366K | 1.01% | 18 |
|
|
2023
Q4 | $15.6M | Hold |
1,431,058
| – | – | 1.49% | 16 |
|
|
2023
Q3 | $11.5M | Hold |
1,431,058
| – | – | 1.29% | 19 |
|
|
2023
Q2 | $15.5M | Hold |
1,431,058
| – | – | 1.6% | 20 |
|
|
2023
Q1 | $9.87M | Hold |
1,431,058
| – | – | 1.23% | 23 |
|
|
2022
Q4 | $5.7M | Hold |
1,431,058
| – | – | 0.64% | 27 |
|
|
2022
Q3 | $9.52M | Hold |
1,431,058
| – | – | 1.14% | 22 |
|
|
2022
Q2 | $6.93M | Hold |
1,431,058
| – | – | 0.81% | 23 |
|
|
2022
Q1 | $13.4M | Hold |
1,431,058
| – | – | 1.3% | 19 |
|
|
2021
Q4 | $17M | Hold |
1,431,058
| – | – | 1.35% | 18 |
|
|
2021
Q3 | $16.3M | Hold |
1,431,058
| – | – | 1.01% | 20 |
|
|
2021
Q2 | $25.7M | Hold |
1,431,058
| – | – | 1.68% | 14 |
|
|
2021
Q1 | $22.2M | Hold |
1,431,058
| – | – | 1.25% | 16 |
|
|
2020
Q4 | $17.5M | Sell |
1,431,058
-1
| -0% | -$14 | 1.1% | 16 |
|
|
2020
Q3 | $18.4M | Hold |
1,431,059
| – | – | 1.71% | 15 |
|
|
2020
Q2 | $14.5M | Sell |
1,431,059
-54,625
| -4% | -$502K | 1.52% | 14 |
|
|
2020
Q1 | $12.1M | Hold |
1,485,684
| – | – | 2.04% | 9 |
|
|
2019
Q4 | $12.8M | Buy |
1,485,684
+225,000
| +18% | +$1.26M | 1.91% | 9 |
|
|
2019
Q3 | $7.77M | Hold |
1,260,684
| – | – | 2% | 6 |
|
|
2019
Q2 | $20.9M | Hold |
1,260,684
| – | – | 10.63% | 3 |
|
|
2019
Q1 | $21.1M | Hold |
1,260,684
| – | – | 8.43% | 4 |
|
|
2018
Q4 | $14.5M | Buy |
1,260,684
+266,321
| +27% | +$5.39M | 4.95% | 6 |
|
|
2018
Q3 | $39.8M | Hold |
994,363
| – | – | 9.03% | 6 |
|
|
2018
Q2 | $28.1M | Hold |
994,363
| – | – | 8.81% | 5 |
|
|
2018
Q1 | $15.2M | Hold |
994,363
| – | – | 8.96% | 3 |
|
|
2017
Q4 | $32.5M | Buy |
+994,363
| New | +$26.8M | 21.3% | 3 |
|
Bain Capital Life Sciences Investors's MRNS Position: Q1 2025 in Review
Bain Capital Life Sciences Investors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 2,693,380 shares — an estimated $1.44M sold.
Bain Capital Life Sciences Investors first reported a position in MRNS in Q4 2017 and held it in 29 quarters. The position peaked at $39.8M in Q3 2018. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Bain Capital Life Sciences Investors reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Bain Capital Life Sciences Investors sold 2,693,380 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $1.44M.
- Bain Capital Life Sciences Investors first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 29 quarters.
- Bain Capital Life Sciences Investors's Marinus Pharmaceuticals, Inc position peaked at $39.8M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2025, filed 15 May 2025.